Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider 2013

Transcription

1 Brochure More information from Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider 2013 Description: Next generation sequencing (NGS) is a disruptive technology that allows scientists to sequence and assemble millions to billions of short DNA reads. This technology is used for applications such as whole genome sequencing, whole exome sequencing (1-2% of the genome that actually encodes proteins) or expression profiling. NGS is the fastest growing and the most attractive segment of the $7.1B genomics space (manufacturer market). With an estimated market size of ~$1.2B in 2012, and a double digit growth rate, we forecast this market will reach $2.1B in 2015, driven by adoption in non-academic customers, especially clinical customers. NGS is poised to revolutionize not only medical research in academic laboratories and Biopharma, but also the healthcare landscape and applied markets (e.g., AgBio, food testing). The second edition of this report reviews the market size, segmentation, growth and trends of the NGS (and third generation sequencing) market. We assess the NGS market across 5 segments: company (Illumina, Life Technologies (Ion Torrent), Roche / 454 Life Sciences, Pacific BioSciences, and Others), product type (Instrument, Reagents, Services), customer (Academia, Biopharma, Applied Markets, Clinical, Other), instrument type (Workhorse, Desktop) and geography (U.S., Europe, Japan, Asia/Pacific, Others). For each of these segments, we provide an annual market size and growth from 2009 to 2015, as well as key growth drivers and moderators. In addition, we review major factors driving future growth including 1) increased reagent usage on an expanding instrument installed base, 2) continued decentralization via desktop sequencers such as Illumina s MiSeq that make the technology accessible to individual academic laboratories and in clinical settings, 3) increased adoption of the technology by new customers (e.g., Applied markets such as AgBio, patients in clinical trials), 4) increased usage for new scientific applications beyond pure sequencing (e.g., expression profiling, ChIP-Seq, methylation studies) and 5) broader adoption of sequencing services (e.g., BGI/Complete Genomics). On the other hand, we discuss four key factors moderating growth including 1) increasing pricing pressure driven by more affordable instrument options and continued technological improvements leading to cheaper cost per base pair and technology commoditization, 2) increasing use of service providers offering an alternative to in-house platform adoption, as many customers don t have the budget for / interest in large capital expenditures for such fast-evolving technologies, 3) continuing workflow and bioinformatics issues, especially for more translational applications, and 4) continuing unfavorable research funding dynamics in the U.S. especially in light of budget sequestration and abroad. In this second edition, we also highlight two key topics: 1) emerging adoption of NGS in clinical settings, as we expect 2015 to an inflection point for this market segment, 2) the continued decentralization driven by desktop sequencers (e.g., Ion Proton, MiSeq). Contents: ABSTRACT EXECUTIVE SUMMARY INTRODUCTION What s new Context and methodology Genomics market overview NEXT GENERATION SEQUENCING MARKET Market overview Applications Market size and growth by product type Market size and growth by instrument type Market size and growth by company Market size and growth by customer base

2 Market size and growth by geography Technology trends in genomics use COMPETITIVE ANALYSIS Illumina Life Technologies / Ion Torrent Roche / 454 Life Sciences Pacific Biosciences BGI / Complete Genomics DESKTOP SEQUENCER: ILLUMINA vs. ION TORRENT NEXT GENERATION SEQUENCING IN THE CLINIC APPENDIX Nanopore sequencing NGS publication analysis DNA target enrichment Additional NGS competitors Platform selection criteria and unmet needs 2010 Review Decommissioning of Sanger instruments Helicos Complete Genomics Table of exhibits Abbreviations Table of exhibits Exhibit 1: WW genomics market by technology (2012E) Exhibit 2: Genomics market drivers and moderators Exhibit 3: WW NGS market ( F) Exhibit 4: Key NGS market drivers and moderators Exhibit 5: NGS application classes and sub-classes Exhibit 6: Platform fit for key experimental classes and subclasses Exhibit 7: WW NGS market by product type ( F) Exhibit 8: Price range of current NGS instruments Exhibit 9: Summary of market trends by product types Exhibit 10: WW NGS market by instrument type ( F) Exhibit 11: Summary of market trends by experimental throughput Exhibit 12: WW NGS market by company ( F) Exhibit 13: WW NGS market by customer type ( F) Exhibit 14: Summary of market trends by customer type Exhibit 15: WW NGS market by geography ( F) Exhibit 16: Summary of market trends by geography Exhibit 17: Past and current cost per million base pairs Exhibit 18: Forecasted number of genome sequenced ( ) Exhibit 19: Sequenced genomes Exhibit 20: Application fit of Illumina platforms Exhibit 21: Specifications and costs of Illumina platforms and reagents Exhibit 22: Capabilities of the HiSeq2000 / 2500 Exhibit 23: Comparison of HiSeq 2500 rapid run mode vs. high output mode Exhibit 24: Recent developments for the HiSeq2000 & 2500 Exhibit 25: Capabilities of the HiSeq1000 Exhibit 26: Recent developments for the HiSeq 1000 Exhibit 27: Capabilities of the GA IIx Exhibit 28: Recent developments for the GA IIx Exhibit 29: Capabilities of the MiSeq Exhibit 30: Benchmarking of MiSeq and PGM Exhibit 31: Recent developments for the MiSeq Exhibit 32: Application fit of Life Technologies platforms Exhibit 33: Specifications and costs of Life Technologies platforms and associated reagents Exhibit 34: Capabilities of the SOLiD 5500 vs 5500xl

3 Exhibit 35: Recent developments for SOLiD instruments Exhibit 36: Capabilities of the Ion Torrent PGM Exhibit 37: Recent developments for PGM instruments Exhibit 38: Capabilities of the Ion Torrent Ion Proton Exhibit 39: Recent developments for Ion Proton instruments Exhibit 40: Application fit of Roche / 454 platforms Exhibit 41: Specifications and costs of Roche / 454 platforms and associated reagents Exhibit 42: Capabilities of the 454 GS FLX and FLX+ Exhibit 43: Recent developments for FLX / FLX+ instruments Exhibit 44: Capabilities of the 454 GS Junior Exhibit 45: Recent developments for GS Junior instruments Exhibit 46: Application fit of PacBio RS vs. competitors Exhibit 47: Specifications and costs of PacBio RS and associated reagents Exhibit 48: Capabilities of the PacBio RS Exhibit 49: Recent developments for PacBio RS instruments Exhibit 50: Recent developments for Complete Genomics services Exhibit 51: Complete Genomics CGA platform capabilities Exhibit 52: Relative market share of desktop sequencers ( F) Exhibit 53: Level of satisfaction with Illumina and Life Technologies desktop sequencers Exhibit 54: Next generation sequencing methodologies Exhibit 55: Selected launched NGS tests Exhibit 56: WW NGS MDx market size by disease area ( F) Exhibit 57: WW NGS MDx market size by NGS approach ( F) Exhibit 58: Drivers and moderators of NGS use in clinic settings Exhibit 59: NGS clinical workflow Exhibit 60: Number of selected NGS publications by field of study ( ) Exhibit 61: Percent of selected NGS publications by field of study ( ) Exhibit 62: Target enrichment market share (2011E) Exhibit 63: High-throughput NGS platform selection criteria Exhibit 64: Low-throughput NGS platform selection criteria Exhibit 65: NGS unmet needs for high throughput platforms Exhibit 66: NGS unmet needs for low throughput platforms Exhibit 67: Sequencing platforms by large genome center (2008) Exhibit 68: Specifications and costs of Heliscope and associated reagents Exhibit 69: Application fit of Heliscope platforms Exhibit 70: Capabilities of the Heliscope Exhibit 71: Recent development for Complete Genomics services Exhibit 72: Complete Genomics services throughput Exhibit 73: Complete Genomics CGA platform capabilities Exhibit 74: Complete Genomics services pricing Exhibit 75: Recent development for Complete Genomics services Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8,

4 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Next Generation Sequencing: Market Size, Segmentation, Growth and Trends by Provider SC Product Formats Please select the product formats and quantity you require: Single User: Site License: Enterprisewide: Quantity USD 3000 USD 4500 USD 6000 * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

5 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World